tiprankstipranks
Elevation Oncology (ELEV)
NASDAQ:ELEV

Elevation Oncology Stock Analysis & Ratings

ELEV Stock Chart & Stats

Day’s Range$3.76 - $3.76
52-Week Range$2.27 - $16.22
Previous Close$3.64
Volume100.00
Average Volume (3M)47.55K
Market Cap$87.43M
P/E Ratio-1.9
Beta0.52
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-1.91


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ELEV FAQ

What was Elevation Oncology’s price range in the past 12 months?
Elevation Oncology lowest stock price was $2.27 and its highest was $16.22 in the past 12 months.
    What is Elevation Oncology’s market cap?
    Elevation Oncology’s market cap is $87.43M.
      What is Elevation Oncology’s price target?
      The average price target for Elevation Oncology is $11.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $12.00 ,the lowest forecast is $11.00. The average price target represents 205.85% Increase from the current price of $3.76.
        What do analysts say about Elevation Oncology?
        Elevation Oncology’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Elevation Oncology’s upcoming earnings report date?
          Elevation Oncology’s upcoming earnings report date is Aug 11, 2022 which is in 86 days.
            How were Elevation Oncology’s earnings last quarter?
            Elevation Oncology released its earnings results on May 05, 2022. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.504 by -$0.236.
              Is Elevation Oncology overvalued?
              According to Wall Street analysts Elevation Oncology’s price is currently Undervalued.
                Does Elevation Oncology pay dividends?
                Elevation Oncology does not currently pay dividends.
                What is Elevation Oncology’s EPS estimate?
                Elevation Oncology’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Elevation Oncology have?
                Elevation Oncology has 23,250,000 shares outstanding.
                  What happened to Elevation Oncology’s price movement after its last earnings report?
                  Elevation Oncology reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.504. Following the earnings report the stock price went up 19.672%.
                    Which hedge fund is a major shareholder of Elevation Oncology?
                    Among the largest hedge funds holding Elevation Oncology’s share is Driehaus Capital Management LLC. It holds Elevation Oncology’s shares valued at 4M.

                      ---

                      Elevation Oncology Stock Analysis

                      The Elevation Oncology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Elevation Oncology

                      Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

                      ---
                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis